{"id":"NCT02272413","sponsor":"Boehringer Ingelheim","briefTitle":"Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer","officialTitle":"A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastin® Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-08","primaryCompletion":"2017-06-30","completion":"2018-11-16","firstPosted":"2014-10-23","resultsPosted":"2020-01-13","lastUpdate":"2020-01-13"},"enrollment":671,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"DRUG","name":"BI 695502","otherNames":[]},{"type":"DRUG","name":"Avastin","otherNames":[]}],"arms":[{"label":"BI 695502","type":"EXPERIMENTAL"},{"label":"Avastin","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this phase III trial is to establish statistical equivalence in terms of efficacy (best overall response rate \\[ORR\\], proportion of patients with complete response \\[CR\\] plus partial response \\[PR\\]) until 18 weeks of first-line treatment with BI 695502 plus chemotherapy versus Avastin® plus chemotherapy followed by maintenance monotherapy with either BI 695502 or Avastin®.","primaryOutcome":{"measure":"Best Overall Response Rate (ORR), Based on Unconfirmed Response Assessment, as Assessed by Central Imaging Review Until 18 Weeks After the Start of Treatment","timeFrame":"Tumor assessment scans were performed at baseline, Cycle 3 (Week 6), Cycle 5 (Week 12) and at Week 18 ±14 days. Best ORR evaluated until confirmed disease progression, unacceptable toxicity, death or up to 18 weeks, whichever happened earlier.","effectByArm":[{"arm":"BI 695502","deltaMin":54,"sd":null},{"arm":"Avastin® US","deltaMin":63.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":189,"countries":["United States","Argentina","Brazil","Bulgaria","Chile","Croatia","Egypt","Germany","Greece","Hungary","Italy","Japan","Malaysia","Mexico","Philippines","Poland","Portugal","Romania","Russia","Serbia","South Africa","South Korea","Spain","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom","Vietnam"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":108,"n":335},"commonTop":["Alopecia","Anaemia","Nausea","Neuropathy peripheral","Neutropenia"]}}